The system was used to evaluate the anti-tumour effect of ROR1CAR-T cells composed of a ROR-1-specific single-chain antibody, an IgG4-Fc-derived hinge, the CD28TM domain, and 4-1BB-CD3ζ or CD28-CD3ζ signaling modules [160]. Here, CD28 is linked to neoplasm.